iglucose: Recently FDA-Cleared, Wireless Diabetes Management System Keeps Everyone Connected

A parent of a child with diabetes or a child of an elderly parent with the disease, wouldn’t it give peace of mind to know that a loved one was not only testing their blood sugar levels regularly as prescribed by their physician, but also to know what their blood sugar levels are as they test at any time day or night? FDA-cleared iglucose™, does it.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Wireless Diabetes Management

Miami Florida USA (PRWEB) November 21, 2011

A parent of a child with diabetes or a child of an elderly parent with the disease, wouldn’t it give peace of mind to know that a loved one was not only testing their blood sugar levels regularly as prescribed by their physician, but also to know what their blood sugar levels are as they test at any time day or night?

FDA-cleared iglucose™ as seen in the feature by Doctors Outlook, a wireless communication system for diabetes management, makes this a reality. What’s more, iglucose functions without the use of a cell phone, telephone, personal computer or wireless data plan.

Imagine this scenario: a 10-year-old child at school who is supposed to test their blood glucose level before lunch. A text message is sent to anyone on their caregiver, family, or doctors list that they have just checked their blood sugar but their levels have fallen dangerously low and they need to eat or drink something immediately. The school nurse also gets a text message and email that the child’s levels are low along with any other person or group desired to be alerted. iglucose creates a communication connection where immediate action can be taken to ensure the child doesn’t suffer an adverse reaction like hypoglycemia from their low blood sugar, which in severe cases can lead to seizures, coma and even death. Of course iglucose also applies to any family member of any age or those who do not have family or loved ones available to check on them.

iglucose which was recently FDA-cleared as a mobile health system and will be available in the market soon, seamlessly communicates glucose readings from leading blood glucose meters to the iglucose diabetes management portal. From there, this important data can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.

iglucose eliminates the burden of keeping manual logbooks of glucose levels and empowers people to be more active with the management of their diabetes. Leading diabetes education organizations recommend that people with diabetes check their blood sugar, keep a logbook of their readings, and take them to their healthcare professional. This is a fundamental cornerstone of diabetes management. Unfortunately, many people with diabetes do not keep logbooks. iglucose solves this problem by automating the process. iglucose not only simplifies life for people with diabetes, but also connects them with loved ones and healthcare professionals who are concerned about their care. This is truly a “win-win” for all.

PositiveID Corporation (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems like the Ricin Detection systems noted in the Digital Journal release. PositiveID focuses primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID was recently recommended in a news release by Vista Partners.

For more information please email:
Bonita Dias
info(at)massmedia77(dot)com
T: 770-331-8823

Copyright © 2011 All rights reserved.
PR: http://www.MassMedia77.com Sound Marketing is Smart Business

Safe Harbor Statement

This report includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2010 and beyond could differ materially from the Company’s current expectations.

Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.        

Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of the MyC3 initiative and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel.

Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with The Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely.

Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.

Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.

###


Contact

Attachments